In one aspect, the disclosure provides a compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof,
wherein

Y is $CHR^5$;
Z is CH, $CR^3$, or N;
n is 1, 2, or 3;
$R^1$ is $–O–L–N(R^7)_2$;
$R^2$ is $C_{1-3}$ alkyl;
each $R^3$ is independently halogen or optionally substituted $C_{1-3}$ alkyl;
$R^4$ is optionally substituted alkyl;
$R^5$ is hydrogen or benzyloxy;

each $R^7$ is independently H or $C_{1-3}$ alkyl;
L is optionally substituted ethylene; and

the compound is not  or .

In some examples, n is 1. In certain examples, the compound is a compound of formula (IA):



(IA)

or a pharmaceutically acceptable salt thereof.
In one aspect, the present disclosure provides a compound of Formula (IA):



(IA)

or a pharmaceutically acceptable salt thereof,
wherein

Y is $CHR^5$;
$R^1$ is $–O–L–N(R^7)_2$;
$R^2$ is $C_{1-3}$ alkyl;
$R^3$ is halogen or optionally substituted $C_{1-3}$ alkyl;
$R^4$ is optionally substituted alkyl;
$R^5$ is hydrogen or benzyloxy;
each $R^7$ is independently H or $C_{1-3}$ alkyl; and
L is optionally substituted ethylene.

In particular examples, $R^3$ is halogen (e.g., fluorine). In further examples, n is 0.
In yet further examples, the compound is a compound of formula (IB):



(IB)

or a pharmaceutically acceptable salt thereof.

In another example, the disclosure provides a pharmaceutical composition including the compound of the disclosure or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. In one aspect, the present disclosure provides a pharmaceutical composition comprising the compound disclosed herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

In yet another example, the disclosure provides a method of treating an oncological disease (e.g., cancer, e.g., those cancers described herein) by administering a therapeutically effective amount of the compound of the disclosure, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of the disclosure to a patient in need thereof. In still another example, the disclosure provides pharmaceutical compositions for use in the treatment of an oncological disease (e.g., cancer, e.g., those cancers described herein). The pharmaceutical compositions include the compound of the disclosure. In a further example, the disclosure provides use of the compound of the disclosure in the manufacture of a medicament for the treatment of an oncological disease (e.g., cancer, e.g., those cancers described herein). In one aspect, the present disclosure provides use of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition disclosed herein in the manufacture of a medicament for treating an oncological disease, wherein the oncological disease is a brain cancer, bladder cancer, breast cancer, central nervous system cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, gastrointestinal stromal tumor, gastric cancer, head and neck cancer, buccal cancer, cancer of the mouth, hepatocellular cancer, lung cancer, melanoma, Merkel cell carcinoma, mesothelioma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, sarcomas, testicular cancer, urothelial cancer, vulvar cancer, Wilm's tumor, rectal cancer, glioblastoma, hepatocellular carcinoma, cholangiocarcinoma, metastatic liver lesions, bone sarcoma, or soft tissue sarcoma. In some examples, the oncological disease is a brain cancer, bladder cancer, breast cancer, central nervous system cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, gastrointestinal stromal tumor, gastric cancer, head and neck cancer, buccal cancer, cancer of the mouth, hepatocellular cancer, lung cancer, melanoma, Merkel cell carcinoma, mesothelioma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, sarcomas, testicular cancer, urothelial cancer, vulvar cancer, or Wilm's tumor. In further examples, the oncological disease is a breast cancer, lung cancer, head and neck cancer, pancreatic cancer, rectal cancer, glioblastoma, hepatocellular carcinoma, cholangiocarcinoma, metastic liver lesions, melanoma, bone sarcoma, soft tissue sarcoma, endometrial cancer, cervical cancer, prostate cancer, or Merkel cell carcinoma.

In some examples, the patient is receiving radiotherapy. In certain examples, the compound or the pharmaceutical composition is administered to the patient concomitantly with the radiotherapy. In particular examples, the compound or the pharmaceutical composition is administered to the patient before radiotherapy. In further examples, the compound or the pharmaceutical composition is administered to the patient after radiotherapy. In yet further examples, the radiotherapy comprises external, internal, brachytherapy, or systemic exposure, e.g., with a radionuclide (e.g., a β-emitting radionuclide (e.g., $^{32}$Phosphorus, $^{67}$Copper, $^{77}$Bromine, $^{89}$Strontium, $^{90}$Yttrium, $^{105}$Rhodium, $^{131}$Iodine, $^{137}$Cesium, $^{149}$Prometheum, $^{153}$Samarium, $^{166}$Holmium, $^{177}$Lutetium, $^{186}$Rhenium, $^{188}$Rhenium, or $^{199}$Gold), α-emitting radionuclide (e.g., $^{211}$Astatine, $^{213}$Bismuth, $^{223}$Radium, $^{225}$Actinium, or $^{227}$Thorium), γ-ray emitting radionuclide (e.g., $^{192}$Iridium), or electron capturing radionuclides (e.g., $^{67}$Gallium, $^{103}$Palladium, or $^{125}$Iodine)), antibody radionuclide conjugate (e.g., $^{90}$Y-ibritumomab tiuxetane, $^{131}$I-tositumomab, $^{225}$Ac-lintuzumab satetraxetan, $^{227}$Th-anetumab corixetan, $^{90}$Y-epitumomab cituxetan, $^{90}$Y-clivatuzumab tetraxetan, $^{177}$Lu-lilotomab satetraxetan, $^{90}$Y-rosopatamab tetraxetan, $^{90}$Y-tabituximab barzuxetan, or $^{90}$Y-tacatuzumab tetraxetan), or another targeted radionuclide conjugate (e.g., $^{131}$I-PSMA, $^{90}$Y-PSMA, $^{177}$Lu-PSMA, or $^{177}$Lu-satoreotide tetraxetan). Preferably, the radiotherapy comprises administering an antibody radionuclide conjugate. In still further examples, the patient is receiving an anti-tumor agent. In other examples, the anti-tumor agent is one or more of cisplatin, oxaliplatin, carboplatin, valrubicin, idarubicin, calicheamicin, or a PARP inhibitor. In yet other examples, the anti-tumor agent is an anti-tumor biological agent and/or anti-tumor immunotherapeutic agent. In still other examples, the compound or the pharmaceutical composition is administered to the patient concomitantly with the anti-

**WHAT IS CLAIMED IS:**

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof,

wherein

Y is $CHR^5$;

Z is CH, $CR^3$, or N;

n is 1, 2, or 3;

$R^1$ is $–O–L–N(R^7)_2$;

$R^2$ is $C_{1\text{-}3}$ alkyl;

each $R^3$ is independently halogen or optionally substituted $C_{1\text{-}3}$ alkyl;

$R^4$ is optionally substituted alkyl;

$R^5$ is hydrogen or benzyloxy;

each $R^7$ is independently H or $C_{1\text{-}3}$ alkyl;

L is optionally substituted ethylene; and

the compound is not  or .

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 1.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (IA):



(IA)

or a pharmaceutically acceptable salt thereof.

4. A compound of Formula (IA):



(IA)

or a pharmaceutically acceptable salt thereof,

wherein

Y is $CHR^5$;

$R^1$ is $–O–L–N(R^7)_2$;

$R^2$ is $C_{1\text{-}3}$ alkyl;

$R^3$ is halogen or optionally substituted $C_{1\text{-}3}$ alkyl;

$R^4$ is optionally substituted alkyl;

$R^5$ is hydrogen or benzyloxy;

each $R^7$ is independently H or $C_{1\text{-}3}$ alkyl; and

L is optionally substituted ethylene.

5. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein $R^3$ is halogen.

6. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein the halogen is fluorine.

7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein one $R^7$ is H, and the remaining $R^7$ is optionally $C_{1\text{-}3}$ alkyl.

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein at least one $R^7$ is isopropyl.

9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein $R^2$ is methyl, ethyl, or isopropyl.

10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein $R^2$ is methyl.

11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein $R^4$ is methyl.

12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein $R^5$ is hydrogen.

13. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein $R^5$ is benzyloxy.

14. A compound selected from the group consisting of:


,

,

,

,

,

,

,

,

,

and pharmaceutically acceptable salts thereof.

15. A compound of the following structure:



or a pharmaceutically acceptable salt thereof.

16. A compound of the following structure:



or a pharmaceutically acceptable salt thereof.

17. A compound of the following structure:



or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising the compound of any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

19. Use of a compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 18 in the manufacture of a medicament for treating an oncological disease, wherein the oncological disease is a brain cancer, bladder cancer, breast cancer, central nervous system cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, gastrointestinal stromal tumor, gastric cancer, head and neck cancer, buccal cancer, cancer of the mouth, hepatocellular cancer, lung cancer, melanoma, Merkel cell carcinoma, mesothelioma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, sarcomas, testicular cancer, urothelial cancer, vulvar cancer, Wilm's tumor, rectal cancer, glioblastoma, hepatocellular carcinoma, cholangiocarcinoma, metastatic liver lesions, bone sarcoma, or soft tissue sarcoma.

20. The use according to claim 19, wherein the patient is one who is receiving radiotherapy.

21. The use according to claim 20, wherein the compound or the pharmaceutical composition is to be administered to the patient concomitantly with the radiotherapy.

22. The use according to claim 20, wherein the compound or the pharmaceutical composition is to be administered to the patient before radiotherapy.

23. The use according to claim 20, wherein the compound or the pharmaceutical composition is to be administered to the patient after radiotherapy.

24. The use according to any one of claims 20 to 23, wherein the radiotherapy comprises external, internal, brachytherapy, or systemic exposure.

25. The use according to any one of claims 20 to 24, wherein the radiotherapy comprises an antibody radionuclide conjugate.

26. The use according to any one of claims 19 to 25, wherein the patient is one who is receiving an anti-tumor agent.

27. The use according to claim 26, wherein the anti-tumor agent is cisplatin, oxaliplatin, carboplatin, valrubicin, idarubicin, calicheamicin, or a PARP inhibitor.

28. The use according to claim 27, wherein the anti-tumor agent is an anti-tumor biological agent or an anti-tumor immunotherapeutic agent.

29. The use according to any one of claims 26 to 28, wherein the compound or the pharmaceutical composition is to be administered to the patient concomitantly with the anti-tumor agent.

30. The use according to any one of claims 26 to 28, wherein the compound or the pharmaceutical composition is to be administered to the patient before the anti-tumor agent.

31. The use according to any one of claims 26 to 28, wherein the compound or the pharmaceutical composition is to be administered to the patient after the anti-tumor agent.